Trial Timelines Advance: Viking Therapeutics has completed enrollment in key Phase 3 studies for its obesity candidate VK2735, with oral formulation trials slated to begin later this year and maintenance dose data anticipated in the coming quarter. Social media observers note that this positions the company for potential regulatory filings toward the end of 2028, assuming smooth data collection and review processes
Big Pharma Interest Builds: Discussions highlight ongoing speculation about whether larger players like Novo Nordisk might pursue partnerships or acquisitions amid the competitive GLP-1 landscape, though some express frustration over the lack of recent deals. Volatility in share price continues to draw attention as investors weigh pipeline progress against broader market risks
Data Release Expectations: Market watchers suggest any clinical updates could be timed after major holidays to maximize impact, with short interest potentially driving near-term price movements. Overall sentiment remains focused on the high-stakes outcomes of upcoming readouts
Note: This discussion summary was generated from an AI condensation of post data
Viking Therapeutics Insider Trading Activity
Viking Therapeutics insiders have traded $VKTX stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales
Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:
- BRIAN LIAN (President & CEO) sold 148,517 shares for an estimated $4,947,888
- GREG ZANTE (Chief Financial Officer) sold 21,217 shares for an estimated $710,141
- MARIANNA MANCINI (Chief Operating Officer) sold 18,217 shares for an estimated $609,635
- NEIL WILLIAM AUBUCHON (Chief Commercial Officer) purchased 4,475 shares for an estimated $149,912
To track insider transactions, check out Quiver Quantitative’s insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint
EARLY ACCESS
Receive VKTX Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
Viking Therapeutics Hedge Fund Activity
We have seen 208 institutional investors add shares of Viking Therapeutics stock to their portfolio, and 227 decrease their positions in their most recent quarter
Here are some of the largest recent moves:
- RAYMOND JAMES FINANCIAL INC removed 1,280,743 shares (-61.7%) from their portfolio in Q2 2026, for an estimated $49,961,784
- STATE STREET CORP added 1,210,837 shares (+27.5%) to their portfolio in Q2 2026, for an estimated $47,234,751
- JPMORGAN CHASE & CO added 915,185 shares (+inf%) to their portfolio in Q2 2026, for an estimated $35,701,366
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 730,690 shares (+inf%) to their portfolio in Q2 2026, for an estimated $28,504,216
- BLACKROCK, INC. removed 690,641 shares (-10.0%) from their portfolio in Q2 2026, for an estimated $26,941,905
- JUMP FINANCIAL, LLC added 579,882 shares (+inf%) to their portfolio in Q2 2026, for an estimated $22,621,196
- TWO SIGMA INVESTMENTS, LP removed 494,728 shares (-11.2%) from their portfolio in Q2 2026, for an estimated $19,299,339
To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint
Viking Therapeutics Price Targets
Multiple analysts have issued price targets for $VKTX recently. We have seen 4 analysts offer price targets for $VKTX in the last 6 months, with a median target of $101.0
- Daniel Brims from Lake Street set a target price of $89.0 on 05/28/2026
- Jeet Mukherjee from BTIG set a target price of $125.0 on 05/01/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $100.0 on 04/30/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $102.0 on 03/23/2026
This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies
